A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD
Status:
Terminated
Trial end date:
2020-12-11
Target enrollment:
Participant gender:
Summary
This 4-week study will evaluate the safety and efficacy of crisaborole ointment 2%;
crisaborole vehicle; topical corticosteroid and topical calcineurin inhibitor, applied twice
daily (BID) in subjects who are at least 2 years of age with mild-moderate AD.
A Sub-Study of Optical Coherence Tomography and Biomarkers in Subjects ages 2 to <18 years
old, with Mild to Moderate Atopic Dermatitis, treated with Crisaborole Ointment, 2% or
Crisaborole Vehicle Ointment or Hydrocortisone Butyrate 0.1% Cream applied BID will also be
conducted at select sites.